OFFICIAL PUBLICATION OF

by its subsidiary APPco

Vyvanse shortage ‘resolved’

AJP Staff 01/05/2024

TGA declares supply issues impacting ADHD medication Vyvanse to be “resolved” Takeda Pharmaceuticals Australia is reporting that supply shortages are no longer impacting its Vyvanse (lisdexamfetamine dimesilate) capsules. Shortages had impacted various strengths of the medication, with the Therapeutic Goods Administration (TGA) reporting that supplies of Vyvanse 50mg capsules had been resolved as of 7 March,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Funding secured for non-8CPA programs

Medschecks and Diabetes MedsCheck are included and funded under the 8CPA. The programs under the 8CPA will be undergoing a…

Anthony Tassone

Eli Lilly clarifies Mounjaro availability

One would think they could have made a commercial decision eith a needle maker to supply requisite number of needles…

Erin Threlfall

Funding secured for non-8CPA programs

This is a big step forward in securing the sustainability and viability of HMRs and RMMRs. Remember there is an…

Debbie Rigby

Funding secured for non-8CPA programs

So well done to the PSA for securing this funding. So important that these very valuable program finally gets looked…

Bente Hart

Vyvanse shortage ‘resolved’

Previous Actions speak louder than words

Next Harmonise RSV vax rules: PSA

Shingles: managing a distressing skin condition

Impetigo: cause and treatment

Topical retinoids: versatile skin care ingredients

Ceramides: what are they and why are they important?

MENU

Previous Actions speak louder than words

Next Harmonise RSV vax rules: PSA

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.